InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (9 ops.)
Explore the detailed record of transactions filed by Denis FORTIER, Chairman & CEO. Insider active across 1 companies, notably EUROBIO-SCIENTIFIC. In total, 19 filings have been recorded. Total volume traded: €4.6m. The latest transaction was filed on 5 December 2024 — Apport à une offre publique d'acquisition. Regulator: AMF. All data is accessible without signup.
Declarations19 total
€146,0825,774 shares@ €25.300.058% mcap0.3% of flow
ActionEuronext Growth Paris
2024DD1009982·
Ideal exit: 1 Sept 2025 (T+270)
€30,3402,000 shares@ €15.170.012% mcap0.1% of flow
ActionEuronext Growth Paris
2023DD943585·
Ideal exit: 13 Sept 2024 (T+270)
€1,61097 shares@ €16.600.0006% mcap0.0% of flow
ActionEuronext Growth Paris
2022DD875203·
Ideal exit: 1 Aug 2023 (T+270)
€16,6701,000 shares@ €16.670.0066% mcap0.0% of flow
ActionEuronext Growth Paris
2022DD870243·
Ideal exit: 24 Jul 2023 (T+270)
€24m25.28 shares@ €945,863.009.44% mcap48.5% of flow
ActionHors plateforme de négociation
2022DD843696·
€24m945,863 shares@ €25.289.44% mcap48.5% of flow
ActionHors plateforme de négociation
2022DD844115·
€500,01319,779 shares@ €25.280.20% mcap16.1% of flow
ActionHors plateforme de négociation
2022DD843701·
€1m51,423 shares@ €25.280.51% mcap41.9% of flow
ActionHors plateforme de négociation
2022DD843702·
€1m51,423 shares@ €25.280.51% mcap41.9% of flow
ActionHors plateforme de négociation
2022DD843703·
019,779 shares0
ActionHors plateforme de négociation
2022DD836341·
016,461 shares0
ActionHors plateforme de négociation
2022DD836342·
0233,383 shares0
ActionHors plateforme de négociation
2022DD836343·
016,461 shares0
ActionHors plateforme de négociation
2022DD836345·
€300,35010,500 shares@ €28.60480.12% mcap0.6% of flow
ActionEuronext Growth Paris
2021DD813860·
€168,5416,180 shares@ €27.2720.067% mcap0.3% of flow
ActionEuronext Growth Paris
2022DD814470·
€29,5201,086 shares@ €27.18210.012% mcap0.1% of flow
ActionEuronext Growth Paris
2022DD815575·
€220,0508,048 shares@ €27.34220.087% mcap0.4% of flow
ActionEuronext Growth Paris
2022DD814038·
€168,0488,402 shares@ €20.00090.066% mcap0.3% of flow
ActionEuronext Growth Paris
2021DD759105·
€419,52220,500 shares@ €20.46450.17% mcap0.9% of flow
ActionEuronext Growth Paris
2021DD744968·
19 of 19 declarations
About Denis FORTIER
Denis Fortier is a senior executive in the French in vitro diagnostics sector and currently serves as Chairman and Chief Executive Officer of Eurobio Scientific. He has held this position since June 2023, after serving as the group’s Chief Executive Officer from 2019. His long involvement with the company is notable: he has also been a member of Eurobio Scientific’s Board of Directors since 2017, giving him a sustained role in the company’s strategic evolution. Fortier holds a Master’s degree in biotechnology and business, and he brings more than 30 years of experience in diagnostics and commercial development. He began his career in marketing and sales roles within diagnostic companies, then became International Director and Head of Business Development at BMD, which later became Theradiag. He subsequently joined the executive management of Inodiag, a startup focused on infectious disease diagnostics, where he was responsible for business development and fundraising. This combination of scientific, commercial, and entrepreneurial experience has shaped his leadership style and operational expertise. At Eurobio Scientific, Fortier is responsible for a broad range of strategic and operational functions, including R&D, production, exports, and commercial development. His role reflects an integrated growth strategy that connects innovation, industrial execution, and international expansion. Under his leadership, Eurobio Scientific has continued to strengthen its position in specialized diagnostics and to broaden its portfolio, including oncology-related products and other high-value diagnostic solutions. He is also a key figure in the company’s governance structure, participating at the highest decision-making level of a listed French diagnostics group. Eurobio Scientific’s governance documents show that he helps define the company’s strategic direction, with a focus on long-term value creation, scientific innovation, and international growth. His profile is that of a hands-on executive who combines corporate leadership with deep sector knowledge and a strong understanding of the diagnostics market.
